Aliases & Classifications for Skin Atrophy

MalaCards integrated aliases for Skin Atrophy:

Name: Skin Atrophy 12 15 17
Atrophic Condition of Skin 12 74
Atrophoderma 12 77
Atrophy - Skin 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2733
NCIt 51 C35163
SNOMED-CT 69 16343004
ICD10 34 L90 L90.9
UMLS 74 C0151514

Summaries for Skin Atrophy

MalaCards based summary : Skin Atrophy, also known as atrophic condition of skin, is related to kindler syndrome and atrophoderma of pierini and pasini. An important gene associated with Skin Atrophy is FERMT1 (Fermitin Family Member 1), and among its related pathways/superpathways are Bladder cancer and Adhesion. The drugs mometasone furoate and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related phenotypes are growth/size/body region and immune system

Wikipedia : 77 Atrophoderma refers to conditions involving skin... more...

Related Diseases for Skin Atrophy

Diseases related to Skin Atrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Related Disease Score Top Affiliating Genes
1 kindler syndrome 31.4 FBLIM1 FERMT1
2 atrophoderma of pierini and pasini 12.6
3 atrophoderma vermiculata 12.6
4 bazex syndrome 12.2
5 follicular atrophoderma, perioral pigmented, with milia and epidermoid cysts 12.1
6 ichthyosis, congenital, autosomal recessive 11 11.5
7 flynn-aird syndrome 11.5
8 keratosis pilaris atrophicans 11.5
9 sequeiros sack syndrome 11.4
10 galloway-mowat syndrome 1 11.1
11 localized lipodystrophy 11.0
12 epidermolysis bullosa simplex, generalized, with scarring and hair loss 11.0
13 hallermann-streiff syndrome 10.9
14 rothmund-thomson syndrome 10.9
15 rombo syndrome 10.8
16 acrogeria, gottron type 10.8
17 cutis marmorata telangiectatica congenita 10.8
18 mandibuloacral dysplasia with type a lipodystrophy 10.8
19 atypical werner syndrome 10.8
20 hypotrichosis 10.4
21 localized scleroderma 10.3
22 ichthyosis 10.2
23 ichthyosis, follicular 10.2
24 cataract 10.0
25 ichthyosis lamellar 1 10.0
26 folliculitis 10.0
27 lichen sclerosus 10.0
28 warthin tumor 9.9 CD44 HBEGF
29 elastosis perforans serpiginosa 9.9
30 epidermoid cysts 9.9
31 lichen sclerosus et atrophicus 9.9
32 marfan syndrome 9.9
33 melkersson-rosenthal syndrome 9.9
34 nevus, epidermal 9.9
35 complement component 2 deficiency 9.9
36 xeroderma pigmentosum, variant type 9.9
37 basal cell carcinoma 1 9.9
38 arthritis 9.9
39 pseudoarthrosis 9.9
40 systemic scleroderma 9.9
41 loeys-dietz syndrome 9.9
42 acrodermatitis chronica atrophicans 9.9
43 keratosis 9.9
44 basal cell carcinoma 9.9
45 acrodermatitis 9.9
46 extramedullary plasmacytoma 9.9
47 plasmacytoma 9.9
48 hypertrichosis 9.9
49 pustulosis of palm and sole 9.9
50 connective tissue disease 9.9

Graphical network of the top 20 diseases related to Skin Atrophy:



Diseases related to Skin Atrophy

Symptoms & Phenotypes for Skin Atrophy

MGI Mouse Phenotypes related to Skin Atrophy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.8 CD44 EBP FERMT1 GJA1 HBEGF KL
2 immune system MP:0005387 9.7 CD44 FBLIM1 FERMT1 GJA1 KL MMP1
3 integument MP:0010771 9.5 CD44 EBP FERMT1 GJA1 HBEGF KL
4 skeleton MP:0005390 9.1 CD44 FBLIM1 GJA1 HBEGF KL MYSM1

Drugs & Therapeutics for Skin Atrophy

Drugs for Skin Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
4
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
5
Racepinephrine Approved Phase 4 329-65-7 838
6
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
7
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
8
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
9
Hydroquinone Approved, Investigational Phase 4 123-31-9 785
10
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 25122-46-7, 25122-41-2 32798 5311051
11
Betamethasone Approved, Vet_approved Phase 4,Phase 1 378-44-9 9782
12
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
13
Coal tar Approved Phase 4 8007-45-2
14
Zinc Approved, Investigational Phase 4 7440-66-6 32051
15
Zinc oxide Approved Phase 4 1314-13-2
16
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Not Applicable 302-79-4 5538 444795
17
Calcium Approved, Nutraceutical Phase 4,Phase 3 7440-70-2 271
18
Calcitriol Approved, Nutraceutical Phase 4,Phase 3 32222-06-3 134070 5280453
19 Anti-Allergic Agents Phase 4
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Immunosuppressive Agents Phase 4,Phase 1,Phase 2,Not Applicable
22 Immunologic Factors Phase 4,Phase 1,Phase 2,Not Applicable
23 Dermatologic Agents Phase 4,Phase 1,Not Applicable
24 Calcineurin Inhibitors Phase 4
25 Peripheral Nervous System Agents Phase 4,Phase 1,Not Applicable
26 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
28 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 Triamcinolone hexacetonide Phase 4,Not Applicable
31 Triamcinolone diacetate Phase 4,Not Applicable
32 triamcinolone acetonide Phase 4,Not Applicable
33 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2,Not Applicable
34 Analgesics, Non-Narcotic Phase 4
35 Antirheumatic Agents Phase 4
36 Analgesics Phase 4
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4
38 Anti-Asthmatic Agents Phase 4,Phase 1
39 Autonomic Agents Phase 4,Phase 1
40 Respiratory System Agents Phase 4,Phase 1
41 Bronchodilator Agents Phase 4
42 Epinephryl borate Phase 4
43 Radiation-Protective Agents Phase 4
44 Protective Agents Phase 4
45 Keratolytic Agents Phase 4,Not Applicable
46 Antioxidants Phase 4
47 Lidocaine, Prilocaine Drug Combination Phase 4
48 Emollients Phase 4,Phase 1
49 Betamethasone-17,21-dipropionate Phase 4,Phase 1
50 Betamethasone sodium phosphate Phase 4,Phase 1

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
2 Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
3 Cutivate Lotion HPA Axis Pediatric Study Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
4 Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma Completed NCT00469183 Phase 4 Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
5 Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
6 Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis Completed NCT01202149 Phase 4
7 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
8 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients Completed NCT00121316 Phase 4 Pimecrolimus;Placebo
9 Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis Completed NCT00733954 Phase 4 clobetasol propionate spray;clobetasol propionate ointment
10 Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis Completed NCT00988637 Phase 4 Vectical™ Ointment weekdays and Clobex® Spray weekends regimen;Clobex® Spray morning and Vectical™ Ointment evening regimen
11 Efficacy of Topical Coal Tar in Children With Atopic Dermatitis Recruiting NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
12 Intralesional Steroids in the Treatment of Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
13 Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis Unknown status NCT02749656 Phase 3 0.25% Desoximetasone cream (Topoxy®);0.25% Desoximetasone cream (Topicorte®);Placebo
14 Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis Completed NCT00658788 Phase 3 clobetasol propionate spray 0.05%;calcitriol ointment
15 A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26) Completed NCT02608476 Phase 3 CB-03-01 cream, 1%;Vehicle cream
16 A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25) Completed NCT02608450 Phase 3 CB-03-01 cream, 1%;Vehicle cream
17 A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 Unknown status NCT01670513 Phase 1, Phase 2 IDP-118 Low Strength;IDP-118 High Strength
18 Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test Completed NCT02111499 Phase 1, Phase 2 LAS41004-IMP1;LAS41004 IMP2;LAS41004 IMP3;LAS41004 IMP4;LAS41004 IMP6;LAS41004 IMP5
19 Novel Compositions for Treating or Preventing Dermal Disorders Recruiting NCT03103893 Phase 1, Phase 2 Rapamycin
20 Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Not yet recruiting NCT03847389 Phase 1, Phase 2 Clobetasol propionate 0.05% Topical Oil
21 A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin Completed NCT02355639 Phase 1 Clobetasol propionate 0.05 % ointment;Betamethasone dipropionate 0.064 % ointment;Petrolatum ointment
22 A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin Completed NCT02392130 Phase 1 Clobetasol propionate 0.05% ointment;LEO 130852A gel 1%;LEO 130852A placebo gel
23 A Study Assessing GW870086's Potential to Cause Skin Thinning Completed NCT01381445 Phase 1 GW870086 0.2%;GW870086 2%;Clobetasol Propionate;Placebo
24 Olaparib and Radiotherapy in Head and Neck Cancer Recruiting NCT02229656 Phase 1 Olaparib
25 Study With a Topical Gel Containing TRIAC and DHEA in Subjects With Skin Atrophy Due to Glucocorticoids Not yet recruiting NCT03783988 Phase 1
26 Nonneoplastic Epithelial Disorders of Vulva and High Intensity Focused Ultrasound Unknown status NCT02890277 Not Applicable Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).
27 The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata Unknown status NCT00999869 Not Applicable Botulinum toxin type A;Triamcinolone acetonide
28 Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging Completed NCT00974480 Not Applicable Tretinoin (Rejuva-A)
29 Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser Completed NCT02416531 Not Applicable Clobetasol propionate
30 Broad Band Light With and Without Radiofrequency Microneedling for Treating Senile Purpura Active, not recruiting NCT03690375 Not Applicable

Search NIH Clinical Center for Skin Atrophy

Genetic Tests for Skin Atrophy

Anatomical Context for Skin Atrophy

MalaCards organs/tissues related to Skin Atrophy:

42
Skin, Testes, Bone, Thyroid, Tongue

Publications for Skin Atrophy

Articles related to Skin Atrophy:

(show top 50) (show all 58)
# Title Authors Year
1
PI3K inhibitors protect against glucocorticoid-induced skin atrophy. ( 30737086 )
2019
2
Syringaresinol Reverses Age-Related Skin Atrophy by Suppressing FoxO3a-Mediated Matrix Metalloproteinase-2 Activation in Copper/Zinc Superoxide Dismutase-Deficient Mice. ( 30798853 )
2019
3
Mineralocorticoid receptor blockade improves glucocorticoid-induced skin atrophy but partially ameliorates anti-inflammatory actions in an irritative model in human skin explants. ( 29178328 )
2018
4
New features of aplasia cutis congenita type 5 - Skin atrophy associated with respiratory insufficiency and multiple intestinal atresia caused by the early death of twin fetus. ( 30316734 )
2018
5
Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy. ( 30410676 )
2018
6
Chaperoning skin atrophy. ( 30559924 )
2018
7
Annular Plaques With Skin Atrophy in a Young Patient. ( 28122082 )
2017
8
Intralesional Treatment With 5-Fluorouracil and Steroid Improves Allergic Contact Dermatitis Without Causing Skin Atrophy and Rebound Lesions. ( 28338541 )
2017
9
Surgical Answer to Intralesional Steroid-Induced Skin Atrophy. ( 27870650 )
2016
10
Resveratrol Derivative-Rich Melinjo Seed Extract Attenuates Skin Atrophy in Sod1-Deficient Mice. ( 26180586 )
2015
11
Acral skin atrophy in an infant: an early clue to Kindler syndrome diagnosis. ( 25764106 )
2015
12
Topical corticosteroid-induced skin atrophy: a comprehensive review. ( 25862024 )
2015
13
Palladium and Platinum Nanoparticles Attenuate Aging-Like Skin Atrophy via Antioxidant Activity in Mice. ( 25333617 )
2014
14
Validation of Dermaphot(Ar) for the assessment of steroid-induced skin atrophy. ( 24488534 )
2014
15
Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. ( 25027750 )
2014
16
Collagen peptide and vitamin C additively attenuate age-related skin atrophy in Sod1-deficient mice. ( 25229861 )
2014
17
Hyalurosome gene regulation and dose-dependent restoration of skin atrophy by retinaldehyde and defined-size hyaluronate fragments in dermatoporosis. ( 25138066 )
2014
18
Validation of Dermaphot(Ar) for the assessment of steroid-induced skin atrophy. ( 23242470 )
2013
19
Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. ( 22512680 )
2012
20
Vulvar skin atrophy induced by topical glucocorticoids. ( 22594868 )
2012
21
Fluorescence spectroscopy as a tool to detect and evaluate glucocorticoid-induced skin atrophy. ( 22249456 )
2012
22
Linear skin atrophy preceding calcinosis cutis in pseudo-pseudohypoparathyroidism. ( 22299648 )
2012
23
Shortened treatment duration of glucocorticoid-induced skin atrophy in rats. ( 21824195 )
2011
24
Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. ( 22110776 )
2011
25
Evaluation of skin atrophy associated with linear atrophoderma of Moulin by ultrasound imaging. ( 21679833 )
2011
26
Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy. ( 20051715 )
2010
27
A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. ( 19755910 )
2009
28
Skin atrophy in cytoplasmic SOD-deficient mice and its complete recovery using a vitamin C derivative. ( 19289104 )
2009
29
Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. ( 19057668 )
2008
30
In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle. ( 18246695 )
2008
31
Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans. ( 17123343 )
2006
32
Glucocorticoid therapy-induced skin atrophy. ( 16689857 )
2006
33
Skin atrophy caused by thiocolchicoside injections. ( 17184273 )
2006
34
Action of topical thyroid hormone analogues on glucocorticoid-induced skin atrophy in mice. ( 16571090 )
2006
35
Hyaluronate fragments reverse skin atrophy by a CD44-dependent mechanism. ( 17177600 )
2006
36
Dose-response effects of tri-iodothyroacetic acid (Triac) and other thyroid hormone analogues on glucocorticoid-induced skin atrophy in the haired mouse. ( 12353707 )
2002
37
Topical tacrolimus and pimecrolimus are not associated with skin atrophy. ( 11903264 )
2002
38
Eyelid skin atrophy associated with chronic usage of ophthalmic steroid ointment, and its successful treatment with the Versapulse laser. ( 11702982 )
2001
39
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. ( 11260007 )
2001
40
Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. ( 9553910 )
1998
41
The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. ( 9990383 )
1998
42
Skin atrophy of the eyelid induced by topical ophthalmic corticosteroids. ( 9686858 )
1998
43
Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. ( 7894098 )
1995
44
In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin. ( 8106754 )
1994
45
Combination of a dual 5-lipoxygenase/cyclooxygenase inhibitor with a glucocorticoid results in synergistic topical antiinflammatory activity without inducing skin atrophy. ( 8225561 )
1993
46
Morphometric computerized analysis as a method to assess skin atrophy caused by corticosteroids. ( 8489771 )
1993
47
0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. ( 1618247 )
1992
48
Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. ( 2768567 )
1989
49
Remote skin atrophy caused by topical steroids. ( 21253139 )
1988
50
Infection and prematurity as the cause of linear skin atrophy, alopecia, anonychia, and tongue lesions? ( 3901928 )
1985

Variations for Skin Atrophy

Expression for Skin Atrophy

Search GEO for disease gene expression data for Skin Atrophy.

Pathways for Skin Atrophy

Pathways related to Skin Atrophy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.23 HBEGF MMP1
2 11.22 CD44 FERMT1 GJA1
3 11.03 CD44 MMP1
4 10.85 CD44 MMP1
5 10.69 GJA1 MMP1
6 10.58 CD44 HBEGF MMP1

GO Terms for Skin Atrophy

Cellular components related to Skin Atrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.35 CD44 EBP GJA1 HBEGF KL
2 apical plasma membrane GO:0016324 9.33 CD44 GJA1 KL
3 focal adhesion GO:0005925 8.92 CD44 FBLIM1 FERMT1 GJA1

Biological processes related to Skin Atrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix disassembly GO:0022617 8.96 CD44 MMP1
2 regulation of heart contraction GO:0008016 8.62 GJA1 HBEGF

Molecular functions related to Skin Atrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.96 HBEGF KL
2 metallopeptidase activity GO:0008237 8.8 MBTPS2 MMP1 MYSM1

Sources for Skin Atrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....